Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, et al. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med. 2013. 52(7):735-44. [Medline].
Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, et al. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis. 2013 Jun 7. 13:269. [Medline]. [Full Text].
Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001 Oct. 23(10):1603-14. [Medline].
Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008 Jun. 28(6):822-32. [Medline].
Zhang Y, Mei H, Wang Q, Xie J, Lv J, Pan X, et al. Peptide binding specificities of HLA-B*5701 and B*5801. Sci China Life Sci. 2012 Sep. 55(9):818-25. [Medline].
Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis. 2017 Apr 11. 17 (1):256. [Medline]. [Full Text].
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7. 358(6):568-79. [Medline].
Dean L, Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, et al. Abacavir Therapy and HLA-B*57:01 Genotype. April 18, 2018. [Medline]. [Full Text].
[Guideline] Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo.nih.gov. Available at https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/37/whats-new-in-the-guidelines-. October 25, 2018; Accessed: November 15, 2018.
[Guideline] Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24. 320 (4):379-396. [Medline].
[Guideline] Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014 May. 95 (5):499-500. [Medline]. [Full Text].
To SW, Chen JH, Wong KH, Chan KC, Tsang OT, Yam WC. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?. Int J STD AIDS. 2013 Jan. 24(1):50-2. [Medline].
Barbarino JM, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul. 10 (4):e1417. [Medline]. [Full Text].
HLA B*5701 status, disease progression, and response to antiretroviral therapy. AIDS. 2013 Oct 23. 27(16):2587-92. [Medline]. [Full Text].
